Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff

Executive Summary

Company had wanted accelerated approval for the antidote for all Factor Xa inhibitors, but will now focus the reversal agent on the two drugs commanding the largest markets – Bristol/Pfizer's Eliquis and J&J/Bayer's Xarelto.


Related Content

Portola's Xarelto/Eliquis Antidote To Be Refiled Next Year
Will Real-World Data Sway Course Of Novel Anticoagulant Market?
Portola Defends AndexXa Antidote Safety, Says Thrombotic Events In Line
Barner Goes Out On A High As Boehringer Ingelheim Returns To Growth
Will Portola’s Betrixaban Data Pass Muster With FDA?
BI's Praxbind US Approval May Boost Pradaxa Sales
Can Praxbind Push Pradaxa Ahead?
Antidote's EU Green Light Brightens Pradaxa Sales Outlook


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst